CLINICAL BENEFIT WITH REGORAFENIB ACROSS SUBGROUPS AND POST-PROGRESSION IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) AFTER PROGRESSION ON IMATINIB (IM) AND SUNITINIB (SU): PHASE 3 GRID TRIAL UPDATE

Author(s):
Casali, P.G.; Reichardt, P.; Kang, Y.; Blay, J.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.; Mehren, M. von; Joensuu, H.; Badalamenti, G.; Blackstein, M.; Cesne, A. le; Schoffski, P.; Maki, R.; Xu, J.; Nishida, T.; Kuss, I.; Laurent, D.; Demetri, G.D.
Published
2012
Publication type
Article / Letter to editor
Date issued
2012-09-30
Language
English
Is part of
Annals of Oncology (2012), Vol. 23, p. 478-479
hdl
1887/99091